Uncovering multiple molecular targets for caffeine using a drug target validation strategy combining A2A receptor knockout mice with microarray profiling

Physiological Genomics

Volumn 37, Issue 3, 2009, Pages 199-210

  Yu, Liqun ^a   Coelho, Joana E ^a   Zhang, Xiaoling ^b   Fu, Yutao ^b   Tillman, Abigail ^a   Karaoz, Ulas ^b   Fredholm, Bertil B ^d   Weng, Zhiping ^b,c   Chen, Jiang Fan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

^c Boston University   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adenosine A2A receptor; Phosphodiesterase; Striatum

Indexed keywords

A2A RECEPTOR; CAFFEINE; PHOSPHODIESTERASE; RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; GENE EXPRESSION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BICUCULLINE; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CLUSTER ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GABA ANTAGONISTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; MALE; MICE; MICE, KNOCKOUT; NEOSTRIATUM; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHODIESTERASE INHIBITORS; RECEPTOR, ADENOSINE A2A; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROLIPRAM;

MUS;

EID: 66349092002     PISSN: 10948341     EISSN: 15312267     Source Type: Journal    
DOI: 10.1152/physiolgenomics.90353.2008     Document Type: Article

References (56)

1. Agardh EE, Carlsson S, Ahlbom A, Efendic S, Grill V, Hammar N, Hilding A, Ostenson CG. Coffee consumption, type 2 diabetes and impaired glucose tolerance in Swedish men and women. J Intern Med 255: 645-652, 2004. (Pubitemid 38703583)
2. Arnett HA, Wang Y, Matsushima GK, Suzuki K, Ting JP. Functional genomic analysis of remyelination reveals importance of inflammation in oligodendrocyte regeneration. J Neurosci 23: 9824-9832, 2003. (Pubitemid 37371596)
3. Ascherio A, Zhang SM, Hernan MA, Kawachi I, Colditz GA, Speizer FE, Willett WC. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 50: 56-63, 2001.
4. Blalock EM, Chen KC, Sharrow K, Herman JP, Porter NM, Foster TC, Landfield PW. Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J Neurosci 23: 3807-3819, 2003. (Pubitemid 36958487)
5. Bracken MB, Triche EW, Belanger K, Hellenbrand K, Leaderer BP. Association of maternal caffeine consumption with decrements in fetal growth. Am J Epidemiol 157: 456-466, 2003. (Pubitemid 36258601)
6. Burton GR, Guan Y, Nagarajan R, McGehee RE Jr. Microarray analysis of gene expression during early adipocyte differentiation. Gene 293: 21-31, 2002.
7. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19: 9192-9200, 1999. (Pubitemid 30228071)
8. Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ, Ongini E, Schwarzschild MA. The role of the D(2) dopamine receptor [D(2)R] in A(2A) adenosine receptor [A(2A)R]-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proc Natl Acad Sci USA 98: 1970-1975, 2001.
9. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, Schwarzschild MA. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21: RC143, 2001.
10. Choi OH, Shamim MT, Padgett WL, Daly JW. Caffeine and theophylline analogues: correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors. Life Sci 43: 387-398, 1988. (Pubitemid 18167984)
11. Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR. Post-analysis follow-up and validation of microarray experiments. Nat Genet 32, Suppl: 509-514, 2002. (Pubitemid 35435154)
12. Ciruela F, Casado V, Rodrigues RJ, Lujan R, Burgueno J, Canals M, Borycz J, Rebola N, Goldberg SR, Mallol J, Cortes A, Canela EI, Lopez-Gimenez JF, Milligan G, Lluis C, Cunha RA, Ferre S, Franco R. Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J Neurosci 26: 2080-2087, 2006. (Pubitemid 43295859)
13. Cnattingius S, Signorello LB, Anneren G, Clausson B, Ekbom A, Ljunger E, Blot WJ, McLaughlin JK, Petersson G, Rane A, Granath F. Caffeine intake and the risk of first-trimester spontaneous abortion. N Engl J Med 343: 1839-1845, 2000.
14. Cui S, Li C, Ema M, Weinstein J, Quaggin SE. Rapid isolation of glomeruli coupled with gene expression profiling identifies downstream targets in Pod1 knockout mice. J Am Soc Nephrol 16: 3247-3255, 2005. (Pubitemid 46179330)
15. Daly JW. Caffeine analogs: biomedical impact. Cell Mol Life Sci 64: 2153-2169, 2007. (Pubitemid 350092417)
16. Daly JW, Fredholm BB. Caffeine-an atypical drug of dependence. Drug Alcohol Depend 51: 199-206, 1998.
17. Daly JW, Shi D, Nikodijevic O, Jacobson KA. The role of adenosine receptors in the central action of caffeine. In: Caffeine and Behavior-Current Views and Research Trends, edited by Gupta BS, Gupta U. Boca Raton, FL: CRC, 1999, p. 1-16.
18. Dickey CA, Loring JF, Montgomery J, Gordon MN, Eastman PS, Morgan D. Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. J Neurosci 23: 5219-5226, 2003. (Pubitemid 36793250)
19. Dudoit S, Shaffer JP, Boldrick JC. Multiple hypothesis testing in microarray experiments. UC Berkeley Division of Biostatistics Working Paper Series 2002.
20. Dupont J, Khan J, Qu BH, Metzler P, Helman L, LeRoith D. Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology 142: 4969-4975, 2001. (Pubitemid 33022373)
21. El Yacoubi M, Ledent C, Menard JF, Parmentier M, Costentin J, Vaugeois JM. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br J Pharmacol 129: 1465-1473, 2000. (Pubitemid 30175720)
22. Fernandes O, Sabharwal M, Smiley T, Pastuszak A, Koren G, Einarson T. Moderate to heavy caffeine consumption during pregnancy and relationship to spontaneous abortion and abnormal fetal growth: a meta-analysis. Reprod Toxicol 12: 435-444, 1998. (Pubitemid 29110875)
23. Fredholm BB. Are methylxanthine effects due to antagonism of endogenous adenosine? Trends Pharmacol Sci 1: 129-132, 1980.
24. Fredholm BB. Astra Award Lecture. Adenosine, adenosine receptors and the actions of caffeine. Pharmacol Toxicol 76: 93-101, 1995.
25. Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51: 83-133, 1999. (Pubitemid 29113867)
26. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552, 2001. (Pubitemid 33136237)
27. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20: 307-315, 2004. (Pubitemid 38262761)
28. Geschwind DH. DNA microarrays: translation of the genome from laboratory to clinic. Lancet Neurol 2: 275-282, 2003. (Pubitemid 38368567)
29. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537, 1999.
30. Halldner L, Aden U, Dahlberg V, Johansson B, Ledent C, Fredholm BB. The adenosine A1 receptor contributes to the stimulatory, but not the inhibitory effect of caffeine on locomotion: a study in mice lacking adenosine A1 and/or A2A receptors. Neuropharmacology 46: 1008-1017, 2004. (Pubitemid 38471954)
31. Halldner L, Lozza G, Lindstrom K, Fredholm BB. Lack of tolerance to motor stimulant effects of a selective adenosine A(2A) receptor antagonist. Eur J Pharmacol 406: 345-354, 2000.
32. Higdon JV, Frei B. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr 46: 101-123, 2006. (Pubitemid 43315921)
33. 2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci 8: 858-859, 2005.
34. Infante-Rivard C, Fernandez A, Gauthier R, David M, Rivard GE. Fetal loss associated with caffeine intake before and during pregnancy. JAMA 270: 2940-2943, 1993. (Pubitemid 24000800)
35. Karcz-Kubicha M, Antoniou K, Terasmaa A, Quarta D, Solinas M, Justinova Z, Pezzola A, Reggio R, Muller CE, Fuxe K, Goldberg SR, Popoli P, Ferre S. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28: 1281-1291, 2003. (Pubitemid 41070898)
36. Kuzmin A, Johansson B, Gimenez L, Ogren SO, Fredholm BB. Combination of adenosine A1 and A2A receptor blocking agents induces caffeine-like locomotor stimulation in mice. Eur Neuropsychopharmacol 16: 129-136, 2006. (Pubitemid 43145819)
37. Lopes LV, Halldner L, Rebola N, Johansson B, Ledent C, Chen JF, Fredholm BB, Cunha RA. Binding of the prototypical adenosine A(2A) receptor agonist CGS 21680 to the cerebral cortex of adenosine A(1) and A(2A) receptor knockout mice. Br J Pharmacol 141: 1006-1014, 2004. (Pubitemid 38510084)
38. Mandel S, Grünblatt E, Youdim M. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J Neural Transm Suppl: 117-124, 2000. (Pubitemid 32037188)
39. Marangos PJ, Paul SM, Parma AM, Goodwin FK, Syapin P, Skolnick P. Purinergic inhibition of diazepam binding to rat brain (in vitro). Life Sci 24: 851-857, 1979. (Pubitemid 9133269)
40. Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, Stoughton R, Burchard J, Slade D, Dai H, Bassett DE Jr, Hartwell LH, Brown PO, Friend SH. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 4: 1293-1301, 1998. (Pubitemid 28512111)
41. McClung CA, Nestler EJ. Regulation of gene expression and cocaine reward by CREB and DeltaFosB. Nat Neurosci 6: 1208-1215, 2003. (Pubitemid 37346042)
42. Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 17: 139-170, 1992.
43. Pinna A, Fenu S, Morelli M. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse 39: 233-238., 2001. (Pubitemid 32099678)
44. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, Tanner CM, Masaki KH, Blanchette PL, Curb JD, Popper JS, White LR. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 283: 2674-2679, 2000. (Pubitemid 30337329)
45. Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 129: 1928-1936, 2005. (Pubitemid 41772970)
46. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550, 2005. (Pubitemid 41528093)
47. Svenningsson P, Nomikos GG, Fredholm BB. Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration. J Neurosci 15: 7612-7624, 1995.
48. Svenningsson P, Nomikos GG, Fredholm BB. The stimulatory action and the development of tolerance to caffeine is associated with alterations in gene expression in specific brain regions. J Neurosci 19: 4011-4022, 1999. (Pubitemid 29222274)
49. Van Dam RM, Feskens EJ. Coffee consumption and risk of type 2 diabetes mellitus. Lancet 360: 1477-1478, 2002. (Pubitemid 35356327)
50. Van Dam RM, Hu FB. Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA 294: 97-104, 2005. (Pubitemid 41002844)
51. Van Dam RM, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. Ann Intern Med 136: 201-209, 2002. (Pubitemid 34118120)
52. Van Dam RM, Willett WC, Manson JE, Hu FB. Coffee, caffeine, and risk of type 2 diabetes: a prospective cohort study in younger and middle-aged U.S. women. Diabetes Care 29: 398-403, 2006. (Pubitemid 44106525)
53. Vik T, Bakketeig LS, Trygg KU, Lund-Larsen K, Jacobsen G. High caffeine consumption in the third trimester of pregnancy: gender-specific effects on fetal growth. Paediatr Perinat Epidemiol 17: 324-331, 2003. (Pubitemid 37328562)
54. Wisborg K, Kesmodel U, Bech BH, Hedegaard M, Henriksen TB. Maternal consumption of coffee during pregnancy and stillbirth and infant death in first year of life: prospective study. BMJ 326: 420, 2003. (Pubitemid 36246311)
55. 2A adenosine receptor genes show similarities to mice given long-term caffeine. J Appl Physiol 106: 631-639, 2009.
56. Yu L, Haverty PM, Mariani J, Wang Y, Shen HY, Schwarzschild MA, Weng Z, Chen JF. Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum. Physiol Genomics 23: 89-102, 2005.